Dr. Mincher is the Principal Investigator for the US DOE Fuel Cycle R&D Programs Fundamental Radiation Chemistry project. He studies the radiation chemistry of organic compounds in aqueous and organic solutions, using steady state and pulse radiolysis techniques, coupled with state-of-the-art analytical measurements to understand the effects of radiation on chemical separations.​

Education in Nuclear Chemistry:

“Remote Radiochemistry Training and E-learning Tools – is it useful? Experience with the CINCH-II tools RoboLab and NucWik”

“The development of the targeted alpha therapy approach and the supporting radiochemistry"

Dr. Frank Bruchertseifer, DG Joint Research Centre (JRC), Germany

After reaching my PhD degree in chemistry at the Technical
University Munich, Institute for Radiochemistry, I worked 4 years for the
German Radiation Protection Office Institute for Radiation Hygiene, Section
Radioecology. In 2004 I joined the Targeted Alpha Therapy
(TAT) group of the European Commission, Joint
Research Centre – JRC-Karlsruhe (formerly known as the Institute of
Transuranium Elements) working in the field of the production and labelling of alpha-emitting radionuclides for targeted alpha therapy with tumor
targeting vectors and their biological investigation and clinical use for TAT.

Gerry Thomas has spent most of her working life unravelling the molecular biology of cancer, thyroid cancer in particular. Thyroid cancer is both caused by, and cured by, exposure to radio iodine. She established the Chernobyl Tissue Bank (www.chernobyltissuebank.com) in 1998 to better understand the molecular nature of radiation induced thyroid cancer and whether this different from thyroid cancer of different aetiology. She has participated in a number of international reviews of the risk of radiation exposure and following the media furore after the accident at Fukushima in 2011 has become increasingly involved in the public communication of radiation risk.